$88.130
-4.054 (-4.60%)收盘时
ABVX 同业对比
In the context of the broader market, ABVX competes directly with industry leaders such as BHC and CRON. With a market capitalization of $7.52B, it holds a leading position in the sector. When comparing efficiency, ABVX's gross margin of N/A stands against BHC's 65.04% and CRON's 53.69%. Such benchmarking helps identify whether Abivax SA is trading at a premium or discount relative to its financial performance.
Abivax SA 财务表现
Abivax has a price-to-sales ratio of 1727.11, which is extremely high, indicating overvaluation relative to sales. The company reported an EPS of -1.71, which was a 58.33% surprise miss compared to the estimate of -1.08, reflecting poor financial performance.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。